Skip to main content

From the helm: Cyclopharm’s (ASX:CYC) MD & CEO, James McBrayer

Jessica Amir
February 5, 2021

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Cyclopharm’s (ASX:CYC) MD & CEO, James McBrayer.

Cyclopharm is a little known Aussie company. Its medical technology is used in 60 countries around the world to help doctors identify lung capacity, as well as find potential blood clots. With earnings mostly coming from Europe, CYC’s US journey gathers momentum with USFDA approval looming. The US is home to the world’s largest nuclear medicine market.

In this video James discusses:

  • (0:31) What CYC does & its “imminent” entry into the US
  • (1:11) Key catalysts to drive share price growth – (1:47) Commercialising the product in the US
  • (2:46) CYC’s product being endorsed to help fight COVID-19 in the US – (3:31) How the company has reduced its risks
  • (4:56) After a 110% rise in share price last year, what can investors expect for the year ahead?

Morning Bell 22 January

Grady Wulff
January 22, 2024

Weekly Wrap 19 January

Sophia Mavridis
January 19, 2024

Morning Bell 19 January

Sam Kanaan
January 19, 2024

Morning Bell 18 January

Grady Wulff
January 18, 2024

Morning Bell 17 January

Grady Wulff
January 17, 2024

Morning Bell 16 January

Grady Wulff
January 16, 2024

Morning Bell 15 January

Sophia Mavridis
January 15, 2024

Weekly Wrap 15 December

Grady Wulff
December 15, 2023

Morning Bell 14 December

Grady Wulff
December 14, 2023

Morning Bell 13 December

Grady Wulff
December 13, 2023